The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer.

Abstract

Farnesoid X receptor (FXR) is a ligand-activated transcription factor involved in the control of bile acid (BA) synthesis and enterohepatic circulation. FXR can influence glucose and lipid homeostasis. Hepatic FXR activation by obeticholic acid is currently used to treat primary biliary cholangitis. Late-stage clinical trials investigating the use of obeticholic acid in the treatment of nonalcoholic steatohepatitis are underway. Mouse models of metabolic disease have demonstrated that inhibition of intestinal FXR signalling reduces obesity, insulin resistance and fatty liver disease by modulation of hepatic and gut bacteria-mediated BA metabolism, and intestinal ceramide synthesis. FXR also has a role in the pathogenesis of gastrointestinal and liver cancers. Studies using tissue-specific and global Fxr-null mice have revealed that FXR acts as a suppressor of hepatocellular carcinoma, mainly through regulating BA homeostasis. Loss of whole-body FXR potentiates progression of spontaneous colorectal cancer, and obesity-induced BA imbalance promotes intestinal stem cell proliferation by suppressing intestinal FXR in Apcmin/+ mice. Owing to altered gut microbiota and FXR signalling, changes in overall BA levels and specific BA metabolites probably contribute to enterohepatic tumorigenesis. Modulating intestinal FXR signalling and altering BA metabolites are potential strategies for gastrointestinal and liver cancer prevention and treatment. In this Review, studies on the role of FXR in metabolic diseases and gastrointestinal and liver cancer are discussed, and the potential for development of targeted drugs are summarized.

• Authors: Lulu Sun, Jie Cai, Frank J Gonzalez
• Journal: Nature reviews. Gastroenterology & hepatology (Nat Rev Gastroenterol Hepatol) Vol. 18 Issue 5 Pg. 335-347 (05 2021) ISSN: 1759-5053 [Electronic] England
• PMID: 33568795 (Publication Type: Journal Article, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antineoplastic Agents
• Bile Acids and Salts
• Biomarkers
• Gastrointestinal Agents
• Receptors, Cytoplasmic and Nuclear
• obeticholic acid
• farnesoid X-activated receptor
• Chenodeoxycholic Acid

Topics

• Animals
• Antineoplastic Agents (pharmacology, therapeutic use)
• Bile Acids and Salts (metabolism)
• Biomarkers (metabolism)
• Chenodeoxycholic Acid (analogs & derivatives, pharmacology, therapeutic use)
• Gastrointestinal Agents (pharmacology, therapeutic use)
• Gastrointestinal Microbiome (drug effects, physiology)
• Gastrointestinal Neoplasms (drug therapy, metabolism, microbiology)
• Humans
• Liver Neoplasms (drug therapy, metabolism, microbiology)
• Metabolic Diseases (drug therapy, metabolism, microbiology)
• Mice
• Receptors, Cytoplasmic and Nuclear (agonists, antagonists & inhibitors, metabolism)
• Signal Transduction (drug effects)